THE AMGEN Experience you can trust
KANJINTI® is indicated for the treatment of:1
- HER2-overexpressing breast cancer
- HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
The first and only Herceptin® biosimilar with SINGLE-TRANSITION study data in the early breast cancer (eBC) seTting1-8
for Herceptin® biosimilarity
The first and only
Herceptin® biosimilar with single-transition study data in the
to Herceptin® IV
Available in a
Multi-dose‡ 420 mg vial1
The same support you’ve come to expect from AMGEN
Established Q-code: Q5117
*NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recognize FDA-approved trastuzumab biosimilars for use in place of trastuzumab (Herceptin®). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
†Current as of April 2021.
‡Multi-dose when reconstituted with Bacteriostatic Water for Injection.